Evidence map›Paper›PMID 41519944›Full record

ArticleCommunications medicine2026

Autoantibody repertoire analysis in paraneoplastic pemphigus reveals novel targets linked to mucocutaneous blistering and bronchiolitis obliterans.

Daniel Eriksson, Maribel Aranda-Guillén, Norito Ishii, Axel Cederholm, Anish Behere, Fahad Ahmed, Juliaana Katto, Sara Öster, Helen Kaipe, Dhifaf Sarhan and 3 more

Abstract read
In one paragraph

Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Daniel Eriksson *Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Maribel Aranda-Guillén *Department of Medicine (Solna), Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-0050-704X
Norito IshiiDepartment of Dermatology, Kurume University School of Medicine, Kurume, Japan.
Axel CederholmScience for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0009-0006-5973-9637
Anish BehereScience for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-2424-3475
Fahad AhmedScience for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Juliaana KattoScience for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Sara ÖsterDepartment of Medicine (Solna), Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-3610-6176
Helen KaipeDepartment of Laboratory Medicine, Division of Immunology, Karolinska Institutet, Stockholm, Sweden.
Dhifaf SarhanDepartment of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden.
Olle KämpeDepartment of Medicine (Solna), Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Takashi HashimotoDepartment of Dermatology, School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Nils LandegrenDepartment of Medicine (Solna), Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. nils.landegren@imbim.uu.se.ORCID http://orcid.org/0000-0002-6163-9540

Funding

Cancerfonden (Swedish Cancer Society) 211513 Pj 01HVetenskapsrådet (Swedish Research Council) 2021-03118
6 · The paper itself

Abstract

backgroundParaneoplastic autoimmunity develops as consequences of immune reactions to cancer and exhibits a wide range of clinical manifestations. The autoimmune signs are often visible before the underlying malignancy is diagnosed, and a prompt diagnosis of paraneoplasia is crucial to enable early tumor detection. We characterized the immune responses underlying the severe mucocutaneous blistering disease paraneoplastic pemphigus.

methodsWe used a two-step approach to proteome-wide autoantibody repertoire analysis and independent validation in patients with paraneoplastic pemphigus (n = 84) and non-paraneoplastic autoimmune blistering diseases (n = 103).

resultsOur findings reveal that paraneoplastic pemphigus features a broad repertoire of disease-specific autoantibodies that mainly target tissue-specific proteins in the skin and mucous membranes. Importantly, we identify SERPINB3 as a major autoantibody target with an expression pattern and clinical association suggesting a role in bronchiolitis obliterans. Autoantibody profiles are similar across neoplasias, except in thymoma patients, who additionally express multiple cytokine autoantibodies.

conclusionsOur findings reveal a disease-defining autoantibody repertoire in paraneoplastic pemphigus that corresponds with clinical manifestations and holds high potential for early cancer detection in patients with blistering disease.

Identifiers

PMID41519944
PMCPMC12873347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.